Swain Laboratory

The central focus of Swain Lab is to investigate molecular mechanisms underlying metabolic adaptation and mitochondrial function in the setting of myocardial ischemia/reperfusion injury, in order to identify novel therapeutic approaches to improve myocardial recovery after acute myocardial infarction. The lab specifically focuses on laying out the detailed molecular signaling during myocardial ischemia versus ischemia reperfusion separately in preclinical model of acute myocardial infarction.
Our publications
In the News
Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial
February 11, 2025
James Udelson, MD, Chief of the Division of Cardiology and Interim Chief Physician Executive of the CardioVascular Center at Tufts Medical Center, in a press release about positive results from the FASTR pilot study, testing an innovative new device for the treatment of patients with acute decompensated heart failure.
In the News
The Flu Is Walloping Mass. In Unusual Second Surge of the Season: ‘It’s Like a Tsunami’
February 11, 2025
Shirley Huang, MD, Chief of General Pediatrics at Tufts Medical Center, in an article about high numbers of flu cases in Massachusetts.
ADPKD guidelines
Announcements
Newly Published Guideline Offers Hope for ADPKD Sufferers
February 12, 2025
Tufts Medical Center nephrologists Ronald Perrone, MD, and Craig Gordon, MD, MS are among an international group of PKD experts who authored the new guideline.
Kapur cardiogenic shock Q and A
Articles
What You Need To Know About Cardiogenic Shock
February 11, 2025
Cardiogenic shock is serious and often sudden. Tufts Medical Center’s Navin Kapur, MD, interventional cardiologist and leading expert in cardiogenic shock, shares what you need to know about this life-threatening condition.